Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
new section at ibox
Chapter 11 - P(Q)LI ...formerly NASDAQ, NYSE, AMEX
SSCCQ -
http://www.smurfit.com/content
Smurfit-Stone Restructuring
http://www.smurfit.com/content/company/restructuring/
http://www.smurfit.com/files/January26AnnouncementPressReleaseFinal.pdf
http://www.smurfit.com/files/February2009MonthlyOperatingReport.pdf
http://www.smurfit.com/files/MarchMORexternalrelease.pdf
...playing also some and _bbb_ too (like WAMUQ) - he's the MOD, it's his decision (asked him / he will answer here)
board rules
Change of Rules (25.01.2009):
NO more OTC/Pinkies, except those which are already listed.
New Stocks must be AMEX minimum, better NYSE / Nasdaq.
ACAS -
Piper Aircraft Acquired by Imprimis to Secure New Growth Opportunities
Date : 05/01/2009 @ 1:10PM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1241198131&article=37538487&symbol=N^ACAS
- New owner fully supports PiperJet development
VERO BEACH, Fla., May 1 /PRNewswire/ -- Piper Aircraft, Inc. today announced that its owner, American Capital Ltd. (NASDAQ:ACAS), has sold its 100 percent stake in the company to Imprimis in a private transaction that aims to secure the long-term success of Florida's 72 year-old General Aviation company. Imprimis is a corporate finance and investment management firm that operates from its offices in Bangkok, Singapore and Brunei Darussalam.
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/piper/38218/
Imprimis intends to invest significant capital in Piper's current operations to strengthen its position in its traditional markets and support the development of key new products such as the PiperJet. Imprimis was drawn to Piper because of the significant potential that it sees for Piper to expand its activities into new markets in Asia Pacific, which is expected to experience steady growth for two- to six-seat aircraft over the next five years, in part due to shifting demographics and increasing demand for pilot training from training schools and flying clubs (commercial and private). Outside of long-term plans for growing market share in Asia, the new shareholders are committed to keeping Piper's headquarters, production and product development facilities in Vero Beach, Fla.
"Imprimis brings a level of support that will propel Piper from its current status as a company with a strong heritage, track record of innovation and great potential to one that is growing and pushing the envelope within General Aviation," said Piper President and CEO James K. Bass. "Imprimis' commitment to grow Piper in both existing and emerging markets comes at a time when we are poised to enter a new era in aviation history."
Imprimis Managing Partner Stephen W. Berger pointed to Piper's substantial track record and respect the company enjoys within the General Aviation industry as being among the primary reasons to acquire Piper.
"Piper's capabilities, its excellent dealer family and extensive customer base, coupled with Imprimis' capability to provide financial support, our dedication to growing the companies we invest in and our contacts within Asia provide fertile ground for Piper to expand its business in the Asian market and throughout the world," said Berger.
Berger said that Imprimis had been looking for some time to invest in an aviation company with a proven track record of prospering in the face of serious challenges. Piper has a strong order book despite challenging times thanks to its position as the only general aviation manufacturer to build and offer aircraft for every general aviation mission. Recent examples include:
-- The Piper Matrix, based on the world-renowned Malibu Mirage, has been a leader in its segment (high-end, cabin-class unpressurized aircraft) and has delivered unprecedented sales in recent Piper history. The Matrix, which received Flying Magazine's Editor's Choice Award 2008, sold out its first full year of production before the first aircraft was delivered in January 2008.
-- The Piper Meridian, Piper's flagship, turboprop aircraft, this year relaunched with the Garmin G1000 avionics suite -- essentially the brain of the aircraft -- to excellent reviews. Much more than an upgraded aircraft, the Meridian with the G1000, its integrated autopilot (the GFC700) and Garmin's Synthetic Vision Technology performs more like a business jet than a personal airplane.
-- The PiperJet continues reaching new milestones with regularity. The PiperJet's first flight took place last July. Since then, Piper test pilots have flown more than 150 hours and to 35,000 feet, where they assessed and in the months ahead will continue to explore the high altitude performance of the aircraft. Piper has 204 contracted orders for the PiperJet, which is more than the company had for the highly successful Piper Meridian at this point in its development.
"Piper's iconic status, coupled with its commitment to product innovation, excellent quality and a management team and workforce second-to-none made it a compelling choice," Berger said. "Imprimis sees this acquisition as a perfect fit as we develop plans for Piper's continued growth in its existing markets and for significant expansion within the Asian markets where much of our focus lies."
Another top priority for Imprimis was a proven track record for innovation and bringing excellent products to market, Berger said.
"Even with the existing worldwide economic recession -- and the toll it has taken on General Aviation, including Piper -- Piper remains strong and well-run, with a strong balance sheet, a comprehensive product line, and a workforce dedicated to providing its customers with excellent products and services," Berger said. "At the same time, Piper has extensive expertise in international markets and the facility to expand into new and emerging markets as well -- all essential to our search criteria."
One of three major U.S. manufacturers of general aviation aircraft, Piper currently manufactures seven models: the Warrior III, Arrow, Seminole, Seneca V, Matrix, Mirage and Meridian. The company is also developing the PiperJet.
About Piper Aircraft, Inc.
Piper Aircraft, Inc. is headquartered in Vero Beach, Fla. Piper's rich legacy is born of 72 years of unparalleled history, with almost 150,000 aircraft brought to market and more than 160 models certified. Approximately 90,000 of those aircraft are still flying and being serviced and supported on every continent by Piper's 65 service centers, 38 dealers and 2,500 field personnel. Piper is the only general aviation manufacturer to build and offer aircraft for every general aviation mission, from trainers and high-performance aircraft for personal and business use, to turbine powered business aircraft and now the PiperJet. For more information about Piper Aircraft and to find an authorized service center near you, please visit http://www.piper.com/.
About Imprimis
Imprimis is a corporate finance and investment management firm that operates from its offices in Bangkok, Singapore and Brunei Darussalam. Imprimis (B) Sdn Bhd, an Imprimis subsidiary, is the manager of the Imprimis Strategic Investment Corporation (NBD) Sdn Bhd, an investment company that seeks to invest in companies that can contribute to the long-term diversification of the Brunei economy. For more information about Imprimis, please visit http://www.imprimis.biz/.
About American Capital
American Capital is a publicly traded private equity firm and global asset manager. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products. Founded in 1986, American Capital has $14 billion in capital resources under management and 10 offices in the U.S., Europe and Asia. For further information, please refer to http://www.americancapital.com/.
http://www.prnewswire.com/mnr/piper/38218DATASOURCE: Piper Aircraft, Inc.
CONTACT: For Piper Aircraft: Mark S. Miller, Chief Corporate
Spokesperson, +1-772-299-2900, Fax: +1-772-978-6597, ; or
For Imprimis: Keith Morrison, Cell: +65-9188-0802, ,
or Jocelyn Ng, Cell: +65-9431-6141, , both of Edelman
Singapore
Web Site: http://www.piper.com/
WaMu seeks to investigate JPMorgan conduct in deal
http://www.finanznachrichten.de/nachrichten-2009-05/13792874-brief-wamu-seeks-to-investigate-jpmorgan-conduct-in-deal-020.htm
01.05.2009 19:17
BRIEF-WaMu seeks to investigate JPMorgan conduct in deal
May 1 (Reuters) - Washington Mutual Inc: (News)
* Seeks court approval to conduct examination of JPMorgan Chase&Co (News/Aktienkurs) -
court documents
* Wamu says wants to investigate potential claims against JPMorgan
based on alleged misconduct leading up to its purchase of wamu assets
- court documents
* Wamu says wants to investigate whether JPMorgan engaged in 'sham
negotiations' and misused and publicly leaked confidential information from
wamu to gain unfair advantage in obtaining assets - court documents
* Wamu says wants to investigate whether fraudulent transfer or
other avoidance claims exist against JPMorgan - court documents
* Wamu says claims against JPMorgan may allow company to hold
JPMorgan responsible for 'destruction' of Washington Mutual Inc and total
losses suffered by its creditors and shareholders - court documents
* Jpmorgan spokeswoman says bank does not comment on pending litigation
((New York Equities Desk; tel: +1 646 223 6000))
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
CTIC pre-market up (high: $0.63)...
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=CTIC&mkttype=pre
The H3 Hummer E-REV (RZ) - next on CNBC
http://www.finanznachrichten.de/nachrichten-2009-05/13791009-raser-technologies-rings-opening-bell-at-new-york-stock-exchange-004.htm
01.05.2009 15:12
Raser Technologies Rings Opening Bell at New York Stock Exchange
Raser’s 100+ MPG Hummer H3 is Showcased on Wall Street
Raser Technologies, Inc. (News) (NYSE: RZ), a leading energy technology company, was invited by the New York Stock Exchange (NYSE) to ring The Opening BellSM at the NYSE today commemorating Raser’s recent listing on the ”Big Board” where it began trading in December 2008.
”We are very pleased to be listed on the New York Stock Exchange, the world’s premier market for publicly traded companies that offers greater access to global capital markets,” said Kraig Higginson, Chairman of Raser Technologies.
"We are pleased with the recent addition of Raser Technologies to our family of NYSE-listed companies," said Scott R. Cutler, NYSE Euronext EVP and Head of Listings, Americas. "Raser offers important contributions that may help solve two of our biggest challenges today by generating clean renewable electric power, and enabling the use of that power in revitalizing our auto industry. We look forward to a long-standing partnership with Raser and its shareholders."
Raser and the NYSE showcased Raser’s Electric Hummer H3 for the media in front of the NYSE building on Broad Street as part of the bell ringing ceremony. The 100+ mpg electric Hummer was recently introduced in Detroit with California Governor Arnold Schwarzenegger attending the unveiling.
”The Electric Hummer H3 was developed in cooperation with GM and its Hummer division with integration support from FEV,” said Higginson. ”The Electric H3, powered by Raser’s proprietary E-REV powertrain, is a four-wheel drive SUV designed to achieve more than 100 mpg in typical local daily driving with near zero emissions by driving its first 40 miles per day in all-electric mode.” Video of the H3 test drive can be seen at www.rasertech.com/hummer.
FEV collaborated with Raser in the development of the Hummer H3 by performing the full vehicle integration including electrical and mechanical design. FEV also developed the software for the hybrid control unit and in-vehicle graphic display.
Gary Rogers, President and CEO of FEV, Inc., commented, ”FEV brings broad experience regarding all of the technical aspects associated with supporting an OEM as they bring a vehicle into production. This vehicle exemplifies what FEV can contribute to projects like this. Our partnership with Raser has been very successful and we look forward to expanding our collaboration with them.”
Raser also showcased the world’s first modular geothermal power plant, which is now delivering clean renewable electricity to the City of Anaheim, CA. The geothermal power plant was constructed in just six months, using a new technology that is capable of generating electricity from more widely available low-to-moderate temperature geothermal resources. The rapid development was made possible by Raser’s proprietary modular power plant design.
”By replicating the success of this modular geothermal power plant across the company’s large portfolio of geothermal holdings, we can now begin to unlock this nation’s vast reserves of geothermal resources that were previously thought to be below viable temperatures for commercial power production,” said Brent M. Cook, CEO of Raser Technologies.
About Raser Technologies
Raser (NYSE: RZ) is an environmental Energy Technology company focused on geothermal power development and technology licensing. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser’s Symetron™ technology developed internally by its Transportation and Industrial segment. Raser’s Transportation&Industrial segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s award-winning Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5954382〈=en
Contacts:
Raser Technologies, Inc.
Richard Putnam, 801-765-1200
Investor Relations
investorrelations@rasertech.com
or
Hayden IR
Cameron Donahue, 651-653-1854
cameron@haydenir.com
or
Public Relations:
Stern&Co.
Richard Stern, 212-888-0044
richstern@sternco.com
or
Alison Simard, 323-650-7117
arsimard@sternco.com
pre-market... -
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=HGSI&mkttype=pre
1 $2.34 (100)
2 $2.46 (500)
3 $2.46 (500)
CETV Reports First Quarter 2009 Results
Date : 04/29/2009 @ 12:01AM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1241170784&article=37479101&symbol=N^CETV
Central European Media Enterprises Reports First Quarter 2009 Results
- Q1 Net Revenues of $141.2 million
HAMILTON, Bermuda, April 29 /PRNewswire-FirstCall/ -- Central European Media Enterprises Ltd. ("CME" or the "Company") (Nasdaq/Prague Stock Exchange - CETV) today announced financial results for the three months ended March 31, 2009.
Net revenues for the first quarter of 2009 were $141.2 million, a decrease of 37%, compared to the first quarter of 2008. Operating income for the quarter decreased $130.0 million to a loss of $(84.5) million and includes an impairment charge of $81.8 million relating to the Company's Bulgarian operations. Net income from continuing operations decreased $62.4 million to a loss of $(46.7) million, and fully diluted income per share decreased by $1.39 to a loss of $(1.05). Segment EBITDA(1) for the first quarter of 2009 was $19.7 million compared to $75.3 million in the first quarter of 2008.
Adrian Sarbu, President and Chief Operating Officer of CME, commented: "The first quarter of 2009 was the toughest in our history across all markets. We foresaw this trend and have managed our sales and costs to limit the impact of the decline in advertising spending. Our leadership remains strong and our advertising share in our core markets increased. Our main priority for the quarter, liquidity, was successfully addressed. Time Warner agreed to invest US$241.5 million in CME. I see this as a sign of confidence in our markets, people and strategy for the future."
(1) Segment Data and Segment EBITDA as used in this press release are all non-US GAAP measures. Beginning in the first quarter of 2009, we no longer describe our operating performance in terms of Segment EBITDA, which reflects our station operating performance but excludes corporate costs. In the following discussion, we describe our operating performance in terms of EBITDA, which is equal to total EBITDA of each of our segments minus corporate costs. We define EBITDA margin as EBITDA expressed as a percentage of Net Revenues. Comparative numbers reflect this change. For further details, including the definition of EBITDA and details of the most directly comparable US GAAP financial measures to non-US GAAP measures, see 'Segment Data' below.
Results for the Three Months Ended March 31, 2009
Net revenues for the three months ended March 31, 2009 decreased by 37% to $141.2 million from $223.0 million for the three months ended March 31, 2008. Operating income for the quarter was a loss of $(84.5) million compared to a gain of $45.5 million for the three months ended March 31, 2008. Net income attributable to the shareholders of CME Ltd. for the quarter was a loss of $(44.4) million compared to income of $14.4 million for the three months ended March 31, 2008. Fully diluted (loss) / income per share for the three months ended March 31, 2009 decreased $1.39 to a loss of $(1.05).
EBITDA, which includes corporate operating costs and stock-based compensation, for the three months ended March 31, 2009 decreased from $65.5 million in the three months ended March 31, 2008 to $ 15.5 million. EBITDA margin for the three months ended March 31, 2009 was 11% compared to 29% in the three months ended March 31, 2008.
...
ProLogis, Q1 2009 Earnings Call Transcript
April 30, 2009
http://seekingalpha.com/article/134449-prologis-q1-2009-earnings-call-transcript?source=feed
ProLogis Reports First Quarter 2009 Results
http://www.finanznachrichten.de/nachrichten-2009-04/13772386-prologis-reports-first-quarter-2009-results-significant-progress-on-de-leveraging-initiatives-008.htm
30.04.2009 00:02
ProLogis Reports First Quarter 2009 Results / - Significant Progress on De-leveraging Initiatives -
DENVER, April 29 /PRNewswire-FirstCall/ -- ProLogis (News), a leading global provider of distribution facilities, today reported first quarter 2009 funds from operations as defined by ProLogis (FFO), excluding significant non-cash items, of $0.86 per diluted share, compared with $1.34 in 2008. Net earnings per diluted share for the first quarter were $0.66 in 2009, compared with $0.69 in 2008.
FFO, including significant non-cash items, was $0.90 per diluted share for the first quarter of 2009, primarily due to gains from early extinguishment of debt, partially offset by ProLogis' share of property fund losses resulting from derivative activity. Net earnings and FFO per diluted share as previously reported for the first quarter of 2008 were reduced by $10.5 million, or $0.04 per diluted share, for the company's retroactive adoption of APB 14-1 and related additional interest expense.
"We have accomplished a great deal in the first part of 2009, making significant progress on our objectives to de-leverage and de-risk the company," said Walter C. Rakowich, chief executive officer. "As a result of our recent equity offering, the sale of certain operations and property fund interests in Asia and property fund contributions, we have generated nearly $2.7 billion of cash in just the past few weeks.
"Taking into consideration additional asset sale and refinancing agreements and the remaining capital requirements related to our development pipeline, we believe we have substantially addressed our anticipated cash needs through 2012. Our swift execution of these de-leveraging initiatives enables us to further enhance our focus on operating property performance, completing and leasing properties in our development portfolio and pursuing opportunities to generate value from our land bank," Rakowich said.
Property Market Fundamentals Soft
During the quarter, industrial property fundamentals continued to reflect global economic weakness and the slowdown in global trade. Throughout the majority of the company's markets, activity levels were reduced and leasing concessions are on the rise. Partially offsetting these trends are higher-than-average customer retention and sharply reduced levels of new supply. ProLogis' same-store net operating income (excluding same-store assets associated with the company's development portfolio), decreased 1.9 percent, reflecting a 1.8 percent decrease in leased percentage and negative rent growth of 4.2 percent for the quarter. Including development portfolio assets, in line with previous reporting, same-store net operating income for the period increased 0.78 percent, with a 0.16 percent increase in leased percentage and negative rent growth of 4.2 percent.
"On average, the company's non-development portfolio was 93.0 percent leased at the end of the first quarter, down from 94.7 percent at year-end 2008, in line with our expectations," Rakowich added. "We have been actively addressing our lease turnovers for the remainder of the year as well as the continued lease up of our development portfolio. Despite the challenging environment, we improved leasing within our development portfolio by 500 basis points, prior to contributions and reflecting the reversal of previous starts."
Asset Sales, Fund Contributions and Debt Repurchases Support De-leveraging Goal
In November 2008, ProLogis outlined a series of actions to achieve a reduction of roughly $2 billion in direct debt by the end of 2009. The plan included reducing the company's development pipeline through fund contributions, asset sales and a halt in all but previously committed development starts, as well as cash savings through a reduction of the common dividend and G&A expenses.
During the first quarter, ProLogis completed dispositions with aggregate proceeds of $1.49 billion, including the previously announced sale of its China operations and Japan property fund interests for $1.35 billion and fund contributions and asset sales of $136 million. Ted R. Antenucci, president and chief investment officer, said, "In addition to these completed transactions at quarter end, we had approximately $700 million of direct-owned assets for sale, 85 percent of which were under contract or letter of intent. In addition, we had another $585 million of development properties greater than 93 percent leased that are available for contribution to our Europe and Mexico property funds throughout the remainder of 2009. Given the significant improvement in our liquidity, we will continue to evaluate the level of asset sales and contributions throughout the year."
William E. Sullivan, chief financial officer, said, "In light of our successful equity offering, we anticipate substantially exceeding our $2 billion de-leveraging goal by the end of 2009 and will continue to pursue opportunities to further de-leverage the company." Between October 1, 2008 and March 31, 2009, the company reduced its outstanding debt by $1.7 billion. "Since the end of the first quarter, we have created incremental de-leveraging of $1.2 billion from the equity offering as well as from additional bond and convertible note buybacks.
"In addition, we have a sizeable base of unencumbered assets on our balance sheet, which provides secured debt financing capacity," said Sullivan. "As such, we intend to utilize the secured debt market to provide additional liquidity to re-finance near-term maturities and have $344 million of such financings in documentation."
Company Declares Common Dividend
Earlier this month, following the issuance of approximately 175 million shares of common stock, the company's Board reduced the 2009 annualized dividend rate to $0.70 per share, including the $0.25 per share paid in February 2009. Sullivan noted, "Our projected annual dividend rate is generally tied to our anticipated taxable income for that same year. While the new dividend level represents approximately the same cash expenditure as the previous dividend amount, the quarterly amount per share for the remainder of the year of $0.15 was established to adjust for the additional shares outstanding."
Also today, the company declared its second quarter common dividend of $0.15 per share, which will be payable on May 29, 2009, to shareholders of record on May 15, 2009.
...
ProLogis
CONTACT: Investor Relations, Melissa Marsden, +1-303-567-5622,
mmarsden@prologis.com, or Media, Krista Shepard, +1-303-567-5907,
kshepard@prologis.com, both of ProLogis; or Financial Media, Suzanne Dawson of
Linden Alschuler&Kaplan, Inc, +1-212-329-1420, sdawson@lakpr.com, for
ProLogis
Web Site: http://www.prologis.com/
ACAS -
http://www.finanznachrichten.de/nachrichten-2009-04/13784264-rpt-update-2-american-capital-sounds-out-buyers-for-europe-arm-020.htm
30.04.2009 18:37
RPT-UPDATE 2-American Capital sounds out buyers for Europe arm
By Simon Meads and Victoria Howley
LONDON, April 30 (Reuters) - Struggling private equity house American Capital Ltd (News) is sounding out buyers for its European portfolio in a deal that could be worth up to $2 billion, three sources familiar with the situation said.
American Capital is looking to sell the European Capital unit -- which had assets under management of $3.5 billion at the end of the third-quarter 2008 -- in its entirety, or could split it up, one of the sources said.
The group has appointed Citigroup as adviser on the process, the source added. Citigroup declined to comment.
'They are out in the market looking to sell on a full portfolio basis,' the source said.
'They are prepared to divide it into sub-portfolios, but they are looking to sell the whole operation,' the source said.
Shares in American Capital opened higher, gaining up to 8.6 percent in early trades on the Nasdaq. The index was up about 2 percent.
A company official in Europe directed queries to the group's U.S. operations, which could not be reached for comment.
The possible sale is a sign of how private equity houses, fabled for their stellar returns in the boom years before the crisis, are now struggling with weakening performance and excessive debts of the companies they own.
Britain's Candover recently took even more drastic measures, entering talks with parties interested in a buy-out and even mulling winding itself up as a last resort.
American Capital has started sounding out secondary firms -- which buy second-hand stakes in private equity portfolios -- but believes parts of the portfolio will also be of interest to other private equity buyout firms, the sources said.
DEBT RESTRUCTURING
At end-March, American Capital completed the buyout of minority shareholders in European Capital, paving the way for the possible sale of the portfolio.
Earlier that month, American Capital posted a $1.7 billion net loss in the fourth quarter of 2008, revealing steep falls in its net asset value had put it in breach of no fewer than three covenants on its $2.3 billion debt facility.
The company said it had been in talks with its lenders since December about restructuring its credit facilities. It had yet to reach an agreement.
The European Capital unit brands itself as a one-stop shop for buyouts, providing all financing for deals in the first instance and syndicating tranches of debt at a later stage, holding a significant portion of mezzanine on its own books.
It also provides pure mezzanine investment, as in the case of French suitcase manufacturer Delsey. While it invests broadly across Europe, its investments focus primarily on the UK, Germany and France.
(Editing by Rupert Winchester and Andrew Macdonald) Keywords: AMERICANCAPITAL/SALE
(simon.meads@thomsonreuters.com; +44 20 7542-9969; Reuters Messaging: simon.meads.thomsonreuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
*** (c)LI-portfolio 0815ax (BigBoards) 05/2009 ***
ACAS ANPI APPY CENX CTIC CPE EMKR FITB GNW HGSI(*) HIG
KV.A MESA(*) MTG NEXM PLD PWAV RZ STP SRZ THC(*) XL XTXI YGE
(*) new
CETV - out, wait/hope for decrease for approx. $10
*** (c)LI-portfolio 0815ax (OTCBB) 04/2009 ***
GNPH NEOM
SRZ ...something is cooking!?
http://shortsqueeze.com/?symbol=srz&submit=Short+Quote%99
Shares Float 40,910,000
Total Shares Outstanding 50,863,040
% Owned by Insiders 11.18 %
% Owned by Institutions 65.00 %
Raser Technologies to Ring Opening Bell at NYSE
28.04.2009 19:20
http://www.finanznachrichten.de/nachrichten-2009-04/13756328-raser-technologies-to-ring-opening-bell-at-nyse-004.htm
Raser Technologies, Inc. (News) (NYSE: RZ), a leading energy technology company, announced today that it will ring The Opening BellSM at the New York Stock Exchange (NYSE) on Friday, May 1, 2009, commemorating its listing on the Big Board where Raser recently began trading in December 2008. The Opening Bell will take place at 9:30 a.m. Eastern time at the New York Stock Exchange.
”To help celebrate this momentous occasion, we will bring our recently unveiled extended-range electric vehicle, the H3 Hummer E-REV,” said Kraig Higginson, Chairman of Raser Technologies. ”This vehicle is powered by Raser’s E-REV powertrain and was developed in conjunction with Raser’s integration partner, FEV, as well as a global automaker. The full-size SUV is a four-wheel drive vehicle and designed to achieve over 100 mpg in typical local daily driving with near zero emissions by driving up to 40 miles per day in all-electric mode.”
The H3 Hummer E-REV will be located on Broad Street just south of Wall Street, in front of the New York Stock Exchange.
Raser will hold a number of media interviews at the NYSE in conjunction with its bell ringing activities to discuss its rapid deployment of geothermal power plants as well as its EREV demonstration vehicle.
”The New York Stock Exchange remains the world’s premier market for publicly traded companies,” said Brent M. Cook, CEO of Raser Technologies. ”We believe the increased exposure to a broader investment community provided by the NYSE will continue to serve the best long-term interests of our stockholders.”
About Raser Technologies
Raser (NYSE: RZ) is an environmental Energy Technology company focused on geothermal power development and technology licensing. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser’s Symetron™ technology developed internally by its Transportation and Industrial segment. Raser’s Transportation&Industrial segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s award-winning Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5950994〈=en
Contacts:
Raser Technologies, Inc.
Richard Putnam, 801-765-1200
Investor Relations
investorrelations@rasertech.com
or
Hayden IR
Cameron Donahue, 651-653-1854
cameron@haydenir.com
or
Public Relations:
Stern&Co.
Richard Stern, 212-888-0044
richstern@sternco.com
Alison Simard, 323-650-7117
arsimard@sternco.com
HGSI reports first profit in 10 years
http://www.bizjournals.com/washington/stories/2009/04/27/daily68.html?surround=lfn
Wednesday, April 29, 2009, 5:34pm EDT | Modified: Thursday, April 30, 2009, 12:58pm
Human Genome Sciences Inc. beat Wall Street’s earnings estimates for the first quarter, ringing up tens of millions of dollars in its first-ever product-related sales and profits.
The Rockville biotech posted $177.3 million in first-quarter revenue, of which $153.8 million, or nearly 87 percent, stemmed from its AbThrax anthrax treatment sales to the federal government. That is leagues ahead of the $12.3 million that the company reported in revenue for the first quarter last year, all composed of payments for hitting certain milestone events in research and development partnerships.
In addition, HGS scored $129.8 million in profits for the first quarter, the first profitable quarter the company logged in at least a decade. In the first quarter of last year, the company posted a $52.7 million loss.
But the positive numbers are temporary, company officials acknowledged, at least until HGS can get its first product approved and successfully marketed -- a move expected for a hepatitis C drug by the second half of 2010.
“We won’t have every quarter like this until we get some of our other big products on the market,” said Tom Watkins, president and CEO of Human Genome Sciences (NASDAQ: HGSI). “AbThrax was an order we received and filled for most of this quarter, and it was certainly at this point a one-time event.”
The company plans to post a little more AbThrax revenue in the second quarter, when its 20,000-dose shipment to the federal government for its national stockpile is expected to complete. But Watkins said HGS is working on additional contracts with the federal government.
“Prospects for follow-on orders for the U.S. government are certainly positive,” he said. “We don’t have anything specific to talk about at this point.”
This first quarter was also helped by the company’s repurchase in February of $106.2 million of its outstanding convertible debt at the discount price of $50 million, all in an effort to cut down the $510 million in previously reported convertible debt set to come due in 2011 and 2012.
That leaves HGS with cash and investments of $396.9 million by the end of the first quarter, compared with $372.9 million at the end of last year. The company said that is enough funding to take its two lead products through the regulatory channels to potential approval and launch. HGSI plans to file this fall for approval to sell its hepatitis C drug, called Albuferon, while its second trademark drug, LymphoStat-B for the treatment of lupus, will release data from its final clinical trials this July and November.
Albuferon had largely disappointed the investor community when its late-stage study data was first revealed in March. It had met its prescribed endpoints of performing as well as current drugs, but with half the number of injections. But Wall Street had hoped Albuferon would prove superior to current standard of care, which they said would be necessary to make it a more marketable drug, and that sent HGSI’s stock tumbling to all-time lows, shedding two-thirds of its value to close at 55 cents.
Analysts have also expressed doubts about LymphoStat-B, pointing to another recent lupus drug candidate that failed its trials. The combination has caused two analysts to downgrade the company’s stock in the last two months, but HGSI officials said the two drugs will play an important role in their commercial portfolio if approved.
“I would tell you that progress on [Albuferon] is continuing, and we feel very good about the prospects of Albuferon to move forward,” Watkins said. “Should it be approved, we believe it will be an important factor, an important option for physicians to consider.”
As for LymphoStat-B, company officials said the drug’s clinical trial setup differentiates it from other failed drugs, adding that the trial had been designed under the purview of the Food and Drug Administration and other experts.
“The failure of other drugs should not give us really any reason to be less confident about LymphoStat-B,” Watkins said. “We feel very good about the phase III trials we have ongoing. That’s why we have the confidence that we do. But you never know until you see the results.”
Human Genome Sciences Inc. Q1 2009 Earnings Call Transcript
April 29, 2009
http://seekingalpha.com/article/134093-human-genome-sciences-inc-q1-2009-earnings-call-transcript?source=feed
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
Date : 04/29/2009 @ 4:05PM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1241116965&article=37496948&symbol=N^HGSI
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
- First HGS product sales achieved with delivery of ABthrax(TM) to U.S. Strategic National Stockpile -
ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (NASDAQ:HGSI) today announced financial results for the quarter ended March 31, 2009, and provided highlights of recent key developments.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )
"In the first quarter of 2009, we achieved our first product sales with ABthrax, and both Albuferon and LymphoStat-B(R) continued to make excellent progress toward commercialization," said H. Thomas Watkins, President and Chief Executive Officer. "We reported positive results from the second of two pivotal trials of Albuferon in chronic hepatitis C, and we plan global marketing applications in fall 2009. We are on track to have the results of our two Phase 3 trials of LymphoStat-B in July and November 2009. We also received a $9 million milestone payment from GSK with the initiation of Phase 3 clinical development of Syncria in type 2 diabetes. In addition, we made solid financial progress during the quarter, reducing our long-term debt and strengthening our cash position."
FINANCIAL RESULTS
HGS reported that revenues for the quarter ended March 31, 2009 increased to $177.3 million, compared with revenues of $12.3 million for the same period in 2008. Revenues included $153.8 million recognized upon the sale and delivery of ABthrax to the U.S. Strategic National Stockpile, $9.0 million recognized from the Syncria agreement with GSK, $8.9 million recognized from the Albuferon agreement with Novartis and $1.6 million recognized from the LymphoStat-B agreement with GSK.
Net income for the quarter ended March 31, 2009 increased to $129.8 million ($0.85 diluted per share), compared with a net loss for the first quarter of 2008 of $52.7 million ($0.39 per share). The net income for the quarter was due primarily to revenue recognized from the delivery of ABthrax under the Company's contract with the U.S. Government. HGS has previously expensed substantially all of the research, development and manufacturing costs related to meeting the terms of the contract.
Cash and investments increased by $24.0 million during the first quarter. As of March 31, 2009, cash and investments totaled $396.9 million, of which $329.3 million was unrestricted and available for operations. This compares with cash and investments totaling $372.9 million as of the end of December 31, 2008, of which $303.6 million was unrestricted and available for operations.
In February 2009, HGS repurchased $106.2 million principal amount of its outstanding convertible debt at a cost of $50.0 million in cash. The repurchase included $82.9 million principal amount of the Company's 2-1/4% Convertible Subordinated Notes Due October 2011, and $23.3 million principal amount of the Company's 2-1/4% Convertible Subordinated Notes Due August 2012.
"The first quarter of 2009 was clearly a very strong quarter for HGS from a financial perspective," said Tim Barabe, Senior Vice President and Chief Financial Officer, HGS. "Our revenues were up substantially and were driven for the first time by product sales. We reduced our long-term debt by more than 20 percent by capitalizing on an opportunity to repurchase $106 million of our outstanding convertible notes at reasonable prices. Our cash position was strengthened and continues to be sufficient to take us through the availability of Phase 3 data, the filing of marketing applications and the launch of our late-stage products."
HIGHLIGHTS OF RECENT PROGRESS
First HGS Product Sales Achieved with Delivery of ABthrax(TM) to U.S. Strategic National Stockpile; $154 Million in Revenue Recognized in the First Quarter
In the first quarter of 2009, HGS achieved its first product sales by initiating the delivery of 20,000 doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for emergency use in the treatment of inhalation anthrax. The Company expects to complete delivery in the current quarter. HGS recognized $153.8 million in ABthrax revenue in the first quarter, including $127.8 million in product sales, and will recognize at least $8.0 million in additional revenue from delivery in the second quarter of 2009.
Also under the contract, HGS plans to file a Biologics License Application (BLA) with the FDA in the second quarter of 2009. The Company will receive an additional $10 million from the U.S. Government upon FDA licensure of ABthrax. ABthrax is being developed under a contract entered into in 2006 with the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS).
Positive Results Announced for Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C; Late-Breaker Results of Both Phase 3 Trials Presented at EASL
In March 2009, HGS reported that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in treatment-naive patients with genotype 1 chronic hepatitis C. As previously reported, Albuferon also met its primary endpoint in ACHIEVE 2/3, which was conducted in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C.
The results of both trials were presented on April 25 in the late-breaker session at the 44th annual meeting of the European Association for the Study of the Liver (EASL) in Copenhagen. The Phase 3 data demonstrate that, with half as many injections, in two pivotal Phase 3 trials, Albuferon achieved efficacy comparable to Pegasys with a positive safety profile. The submission of global marketing applications for Albuferon is planned in fall 2009, following discussions with the FDA and other regulatory authorities. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.
LymphoStat-B(R) Phase 3 Results Expected in July and November 2009
HGS expects to report the first Phase 3 data for LymphoStat-B (belimumab) in July 2009 from the BLISS-52 trial, with results from BLISS-76 anticipated in November 2009. BLISS-52 and BLISS-76 are the largest clinical trials ever conducted in lupus patients. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.
$9 Million Milestone Payment Received from GSK Following Initiation of Phase 3 Development of Syncria(R)
HGS received a $9.0 million milestone payment during the first quarter of 2009, following GSK's initiation of a Phase 3 clinical trial program to evaluate Syncria (albiglutide) in the long-term treatment of type 2 diabetes mellitus. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183.0 million, including $33.0 million received to date. HGS is also entitled to single-digit royalties on worldwide sales if Syncria is commercialized.
HGS and Morphotek Agree to Collaborate on Discovery, Development and Commercialization of Therapeutic Antibodies for Oncology and Immunology
In March 2009, HGS and Morphotek, Inc., a subsidiary of Eisai Corporation of North America, entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies in the fields of oncology and immunology that specifically target antigens discovered by HGS. Morphotek will be responsible for validating targets discovered through genomic research provided by HGS, generating and developing all monoclonal antibody candidates using proprietary Morphotek technologies, and conducting early preclinical proof-of-concept studies. HGS and Morphotek will have the right to participate in the development and commercialization of each antibody candidate.
CONFERENCE CALL
HGS management will hold a conference call to discuss this announcement today at 5 PM Eastern time. Investors may listen to the call by dialing 877-591-4959 or 719-325-4901, passcode 2810740, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719-457-0820, confirmation code 2810740. Today's conference call also will be webcast and can be accessed at http://www.hgsi.com/. Investors interested in listening to the live webcast should log on before the conference call begins to download any software required. Both the audio replay and the archive of the conference call webcast will remain available for several days.
ABOUT HUMAN GENOME SCIENCES
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.
The Company's primary focus is rapid progress toward the commercialization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 clinical trials of LymphoStat-B are ongoing, with results expected in July and November 2009.
In January 2009, HGS began delivery of 20,000 doses of ABthrax(TM) (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. The Company also has several drugs in earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria(R) (albiglutide), currently in Phase 3 development as a potential treatment for type 2 diabetes.
For more information about HGS, please visit the Company's web site at http://www.hgsi.com/. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to or by calling HGS at (301) 610-5790, extension 3550.
HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.
SAFE HARBOR STATEMENT
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has begun shipment of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to acceptance of future shipments and FDA's approval of the Company's Biologics License Application for ABthrax, if and when it is submitted. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
(See selected financial data on following pages.)
HUMAN GENOME SCIENCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended March 31, 2009 2008 (dollars in thousands, except share and per share amounts) Revenue: Product sales $127,769 $- Manufacturing and development services 29,116 - Research and development collaborative agreements 20,392 12,275 Total revenue 177,277 12,275
Costs and expenses: Cost of product sales 8,177 - Cost of manufacturing and development services 3,351 - Research and development expenses 53,675 72,691 General and administrative expenses 14,279 16,011 Total costs and expenses (a) 79,482 88,702 Income (loss) from operations 97,795 (76,427) Investment income 4,296 6,707 Interest expense (15,730) (15,517) Gain on extinguishment of debt 38,873 - Gain on sale of long-term equity investment 5,259 32,518 Other expense (680) - Income (loss) before taxes 129,813 (52,719) Provision for income taxes - - Net income (loss)(b) $129,813 $(52,719) Basic net income (loss) per share $0.96 $(0.39) Diluted net income (loss) per share $0.85 $(0.39) Weighted average shares outstanding, basic 135,755,471 135,284,778 Weighted average shares outstanding, diluted 163,423,487 135,284,778
(a) Includes stock-based compensation expense of $2,935 ($0.02 per basic and diluted share) and $4,463 ($0.03 per basic and diluted share) for the three months ended March 31, 2009 and 2008, respectively.
(b) HGS adopted FASB Staff Position No. APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) ("FSP APB 14-1") effective January 1, 2009, which required restatement of prior periods, as applicable. Includes amortization of debt discount of $6,398 ($0.05 per basic share and $0.04 per diluted share) for the three months ended March 31, 2009. 2008 results have been restated and now include amortization of debt discount of $5,854 ($0.04 per basic and diluted share) for the three months ended March 31, 2008. Results for 2009 and 2008 also include certain other immaterial adjustments arising from the adoption of FSP APB 14-1.
CONSOLIDATED BALANCE SHEET DATA: As of As of March 31, 2009 December 31, 2008(c) (dollars in thousands) Cash, cash equivalents and investments (d) $396,852 $372,939 Total assets (d) 735,365 686,832 Convertible subordinated debt (e) 334,269 417,597 Lease financing 247,061 246,477 Total stockholders' deficit (3,448) (136,304)
(c) As noted in footnote (b) above, FSP APB 14-1 required restatement of prior periods. Total assets, convertible subordinated debt, and total stockholders' deficit as previously reported were $674,164, $510,000, and $(241,375), respectively, as of December 31, 2008.
(d) Includes $67,569 and $69,360 in restricted investments at March 31, 2009 and December 31, 2008, respectively.
(e) Convertible subordinated debt is net of unamortized debt discount of $69,581 and $92,403 as of March 31, 2009 and December 31, 2008, respectively. Convertible subordinated debt at face value is $403,850 and $510,000 as of March 31, 2009 and December 31, 2008, respectively.
http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO
http://photoarchive.ap.org/
DATASOURCE: Human Genome Sciences, Inc.
CONTACT: Media, Jerry Parrott, Vice President, Corporate Communications,
+1-301-315-2777, or Investors, Peter Vozzo, Senior Director, Investor
Relations, +1-301-251-6003, both of Human Genome Sciences, Inc.
Web Site: http://www.hgsi.com/
Raser Technologies to Ring Opening Bell at NYSE
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37372845
RZ to Ring Opening Bell at NYSE
http://www.finanznachrichten.de/nachrichten-2009-04/13756328-raser-technologies-to-ring-opening-bell-at-nyse-004.htm
28.04.2009 19:20
Raser Technologies to Ring Opening Bell at NYSE
Raser Technologies, Inc. (News) (NYSE: RZ), a leading energy technology company, announced today that it will ring The Opening BellSM at the New York Stock Exchange (NYSE) on Friday, May 1, 2009, commemorating its listing on the Big Board where Raser recently began trading in December 2008. The Opening Bell will take place at 9:30 a.m. Eastern time at the New York Stock Exchange.
”To help celebrate this momentous occasion, we will bring our recently unveiled extended-range electric vehicle, the H3 Hummer E-REV,” said Kraig Higginson, Chairman of Raser Technologies. ”This vehicle is powered by Raser’s E-REV powertrain and was developed in conjunction with Raser’s integration partner, FEV, as well as a global automaker. The full-size SUV is a four-wheel drive vehicle and designed to achieve over 100 mpg in typical local daily driving with near zero emissions by driving up to 40 miles per day in all-electric mode.”
The H3 Hummer E-REV will be located on Broad Street just south of Wall Street, in front of the New York Stock Exchange.
Raser will hold a number of media interviews at the NYSE in conjunction with its bell ringing activities to discuss its rapid deployment of geothermal power plants as well as its EREV demonstration vehicle.
”The New York Stock Exchange remains the world’s premier market for publicly traded companies,” said Brent M. Cook, CEO of Raser Technologies. ”We believe the increased exposure to a broader investment community provided by the NYSE will continue to serve the best long-term interests of our stockholders.”
Fifth Third, Key stock performance could indicate stress test results
Tuesday, April 28, 2009, 11:17am EDT
http://www.bizjournals.com/cincinnati/stories/2009/04/27/daily17.html?surround=lfn
If investor action on Monday is any indication of the results of the federal government’s stress tests of the 19 largest U.S. banks, Fifth Third Bancorp is in decent shape and KeyCorp might not have done as well.
Government officials gave preliminary results to representatives from each of the banks Friday. The banks aren’t allowed to talk publicly about the tests, which aim to gauge their ability to withstand worsening economic conditions. But Wall Street’s speculation, if not information, points to Cleveland-based KeyCorp (NYSE: KEY), Capital One Financial Corp. (NYSE: COF) and Regions Financial Corp. (NYSE: RF) as the three banks likely to take the worst hit from the results.
Those three bank stocks fell 12 percent Monday. Of the other largest banks (one bank is privately held) none fell more than 9 percent Monday.
Meanwhile, plenty of speculation has focused on downtown-based Fifth Third Bancorp’s (Nasdaq: FITB) exposure to commercial real estate loans, a growing problem area.
“Current focus seems to be on some regional banks having large exposure to commercial real estate loans, like Regions Financial, SunTrust, KeyCorp and Fifth Third Bancorp,” Neena Mishra, an analyst at Chicago-based Zacks Investment Research Inc., wrote in a commentary on Monday. “These banks appear to be undercapitalized to absorb the future losses as (commercial real estate) pricing continues to deteriorate sharply.”
But investors aren’t too worried. Fifth Third’s stock fell just 2.4 percent Monday, making it the fifth-best stock on the day out of the 18 stress-tested banks.
Stress-test results are scheduled to be made public May 4.
Meanwhile, Deutsche Securities launched coverage of Fifth Third’s stock Monday. It started with a “hold” rating on the shares. That joins seven analysts with “hold” ratings on the stock, according to Zacks. Two have “buy” ratings and two have “sell” ratings.
And investors bought an inordinately high number of put options Monday, said Nick Perry, analyst at Blue Ash-based Schaeffer’s Investment Research Inc. Put options allow investors to guard against a further decline in the stock.
Perry noted that Fifth Third has rallied off of its low. It jumped from $1.03 in late February to $4.83 April 17. But it has pulled back to its near-term support levels, closing at $3.62 on Monday.
“A successful hold here would suggest buyers are still willing and able to step in,” Perry wrote in a commentary. “Of particular interest to me would be situations where we see put activity on stocks that are still in intermediate-term uptrends. This would be a potentially encouraging sign from the contrarian perspective.”
HGSI -
added to LONGTIME-portfolio @ 1,19€
did additional dd...
IMO (could become a MONSTER)
http://www.hgsi.com/
Three Products in Late-Stage Development
We now have three promising products in late-stage development, moving toward commercialization. We have reported the positive results of two Phase 3 trials of Albuferon®, and we plan to file global marketing applications in fall 2009. Two Phase 3 trials are ongoing for LymphoStat-B® in patients with lupus, with results expected in July and November 2009. We are developing both of these products in collaboration with world leaders in the pharmaceutical industry. Also in late-stage development is ABthrax™, which offers a new way to address the threat of inhalation anthrax and is being developed under a contract with the U.S. Government.
High-Potential Pipeline
Right behind these late-stage products is an emerging, high-potential mid-stage pipeline, led by our TRAIL receptor antibodies for cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
---------------------------------------------------------------
http://www.hgsi.com/products.html
CLINICAL DEVELOPMENT PIPELINE
HGS has a well balanced and deep portfolio of novel drugs directed toward diseases that represent significant unmet medical need. Three of these products are in late-stage development.
In March 2009 and December 2008, we reported positive Phase 3 results from our Phase 3 trials of Albuferon® (albinterferon alfa-2b) in patients with chronic hepatitis C. Filings of global marketing applications are planned in fall 2009. Two Phase 3 trials are ongoing for LymphoStat-B® (belimumab) in patients with systemic lupus erythematosus (SLE), with results expected in July and November 2009. ABthrax™ (raxibacumab) is in late-stage development for the treatment of inhalation anthrax.
Right behind these late-stage products is an emerging high-potential mid-stage pipeline, led by our anti-cancer products, HGS-ETR1 (mapatumumab) and HGS 1029, an IAP inhibitor – both for the treatment of cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
---------------------------------------------------------------
Q4/2008 QUARTERLY RESULT
http://www.hgsi.com/quarterly-results/human-genome-sciences-announces-fourth-quarter-and-full-year-2008-financial-results-and-key-develop.html
52wk Range: 0.27 - 27.21
...hope it reaches $13.50 at the end of the year
Short interest and more -
http://shortsqueeze.com/?symbol=srz&submit=Short+Quote%99
Shares Float 40,910,000
Total Shares Outstanding 50,863,040
% Owned by Insiders 11.18 %
% Owned by Institutions 65.00 %
Record Date 2009-April(15)
Sector Healthcare
Industry Long-Term Care Facilities
nice move since 03/09,2009
...had to select between both and took HGSI
(no more cash on hand)
...your DVAX looks nice too! (Mahlzeit)
playing HGSI
pre-market (now) $1.65
http://shortsqueeze.com/?symbol=hgsi&submit=Short+Quote%99
Human Genome Sciences Inc. $ 1.30
HGSI
Short Interest (Shares Short) 9,178,900
Days To Cover (Short Interest Ratio) 4.1
Short Percent of Float 7.02 %
Short Interest - Prior 9,595,600
Short % Increase / Decrease -4.34 %
Short Squeeze Ranking™ -24
% From 52-Wk High ($ 8.00 ) -515.38 %
% From 52-Wk Low ($ 0.45 ) 65.38 %
% From 200-Day MA ($ 2.22 ) -70.77 %
% From 50-Day MA ($ 1.11 ) 14.62 %
Price % Change (52-Week) -82.50 %
Shares Float 130,690,000
Total Shares Outstanding 135,745,696
% Owned by Insiders 8.41 %
% Owned by Institutions 77.20 %
Market Cap. $ 176,469,405
Trading Volume - Today 2,410,815
Trading Volume - Average 2,243,400
Trading Volume - Today vs. Average 107.46 %
Earnings Per Share -1.81
PE Ratio
Record Date 2009-AprilB
Sector Healthcare
Industry Biotechnology
Exchange NAS
http://ih.advfn.com/p.php?pid=nmona&cb=1240832302&article=37435117&symbol=N^HGSI
Date : 04/25/2009 @ 10:00AM
Source : PR Newswire
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with
- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) -
ROCKVILLE, Md., April 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (NASDAQ:HGSI) today reported that the final results of two pivotal Phase 3 trials demonstrate that Albuferon(R) (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in the treatment of patients with chronic hepatitis C. The Phase 3 results were the subject of two late-breaker oral presentations today in Copenhagen at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL). Albinterferon alfa-2b is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )
"The Phase 3 data presented at EASL show that Albuferon, with half the injections, achieved a rate of sustained virologic response comparable to Pegasys," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "Importantly, the rates of serious and/or severe adverse events were also comparable in these studies. We plan to file global marketing applications in fall 2009, following discussions with regulatory authorities - and we believe that Albuferon, assuming licensure, could become a leading treatment for chronic hepatitis C."
The Phase 3 studies, known as ACHIEVE 1 and ACHIEVE 2/3, evaluated albinterferon alfa-2b vs. peginterferon alfa-2a, in combination with ribavirin, for use in the treatment of interferon-naive patients with chronic hepatitis C. ACHIEVE 1 was conducted in patients infected with genotype 1 virus, and ACHIEVE 2/3 was conducted in patients with genotypes 2 and 3 virus. The two studies treated a combined total of 2255 treatment-naive patients.
"The results of two Phase 3 trials demonstrate that 900-mcg albinterferon alfa-2b administered every two weeks provides efficacy comparable to peginterferon alfa-2a administered weekly, with a positive safety profile," said David Nelson, M.D., Professor of Medicine, Medical Director of Liver Transplantation, and Chief of the Hepatobiliary Disease Section, University of Florida. Dr. Nelson presented the results from ACHIEVE 2/3.
Stefan Zeuzem, M.D., Professor of Medicine and Chief, Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany, presented the ACHIEVE 1 results, and said, "The data presented at EASL suggest that albinterferon alfa-2b has the potential to become an important and novel treatment option for patients with chronic hepatitis C."
...
http://finance.yahoo.com/news/Human-Genome-Sciences-to-prnews-15002108.html?.v=1
ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - News) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended March 31, 2009. These results are expected to be disclosed on Wednesday, April 29, 2009, after the capital markets close.
pre-market now: $1.70
pre-market now: $1.54
XL - LINK to yahoo.com
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_X/threadview?m=te&bn=20258&tid=13863&mid=13863&tof=1&frt=2#13863
!! but - do your own dd (I'm holding...)
http://shortsqueeze.com/?symbol=xl&submit=Short+Quote%99
Short Interest (Shares Short) 28,467,200
Record Date 2009-April(15)
Shares Float 337,460,000
Total Shares Outstanding 342,210,169
% Owned by Insiders 0.17 %
% Owned by Institutions 98.30 %
Market Cap. $ 3,066,203,114
Kraig Higginson (Director) on shopping tour
http://www.secform4.com/insider-trading/1264975.htm
BuckeyeMike could/should add me as an assistant, (or withdraw as mod - like BO "yes I can" )
...so I can redesign the ibox, add some stuff from webpage
sorry - only "free member", so I can't PM to BuckeyeMike
(would you send a PM and ask him?? - thanks!)...
*******************************************************************************************
Raser Technologies UNVEILS 100+ MPG PLUG-IN HYBRID Hummer at THE SAE World Congress IN DETROIT
Raser Begins Delivering Power to Anaheim, Califorina
Raser Technologies And Utah Governor Jon Huntsman Celebrate Earth Week
Short Interest Highlights - TWSJ
http://online.wsj.com/mdc/public/page/2_3062-nyseshort-highlites.html?mod=topnav_2_3024
XL is touching MA200 (on daily basis)
...let it in - it's OK
...in since last year! (but: rules are rules)
...then I can also post about NEOM!!!